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Recent Development 
Metabolite Labs and Patentable Subject Matter: A Review of 
Federal Circuit and PTO Precedent was Narrowly Averted, 
but for How Long? 
Michelle E. Dawson∗ 
 
One cannot patent “laws of nature, natural phenomena, 
and abstract ideas.”1 On October 31, 2005, the United States 
Supreme Court granted certiorari, in the case of Lab. Corp. of 
Am. Holdings v. Metabolite Labs., Inc., to determine whether 
claim thirteen of Competitive Technologies, Inc.’s (CTI) U.S. 
Patent No. 4,940,658 (“the ‘658 patent”) was invalid because it 
recited nothing more than a natural phenomenon.2  On June 
22, 2006, after hearing oral arguments, the Court dismissed the 
writ as “improvidently granted”.3  Despite ultimate dismissal of 
the writ, the question remains whether the Federal Circuit and 
the United States Patent and Trademark Office’s (PTO) 
interpretation of Supreme Court precedent and 35 U.S.C. § 101 
on subject matter patentability will be reexamined and possibly 
limited or altered by the Supreme Court in the near future. 
PATENTABLE SUBJECT MATTER 
Section 101 identifies what subject matter may be entitled 
       ©   2007 Michelle E. Dawson.       
       ∗   University of Minnesota JD candidate (2008) and MS candidate in the 
School of Public Health (2008).  The author would like to thank Professor 
David Adelman for suggesting the topic for this paper. 
 1. Diamond v. Diehr, 450 U.S. 175, 185 (1981). 
 2. Lab. Corp. of Am. Holdings v. Metabolite Labs., 126 S. Ct. 543 (2005) 
(granting the petition for writ of certiorari). 
 3. Lab. Corp. of Am. Holdings v. Metabolite Labs., 126 S. Ct. 2921, 2921 
(2006) (dismissing the writ of certiorari as improvidently granted). 
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to a patent.4  In Diamond v. Diehr, the leading case on 
patentable subject matter and the last case on this topic the 
Supreme Court has decided, the Court recognized that 
“Congress intended statutory subject matter to ‘include 
anything under the sun that is made by man.’”5  The Court, 
however, also reiterated its long-standing determination that 
despite the broad scope of patentable subject matter “laws of 
nature, natural phenomena, and abstract ideas” are not 
patentable, but rather free for all to use.6  Therefore, as is often 
noted, Newton could not have patented the law of gravity and 
Einstein could not have patented E = mc².7  Drawing clear 
distinctions between what constitutes permissible subject 
matter considered broadly, as Congress intended, and what 
constitutes impermissible subject matter because the claim 
involves a natural law, natural phenomenon, or abstract idea 
has proven challenging for the Court.8  Despite the difficulty 
 4. 35 U.S.C.A. § 101 (2006). “Whoever invents or discovers any new and 
useful process, machine, manufacture, or composition of matter, or any new 
and useful improvement thereof, may obtain a patent therefor, subject to the 
conditions and requirements of this title.”  Id. 
 5. Diehr, 450 U.S. at 182 (quoting S. Rep. No. 82-1979, at 5 (1952), as 
reprinted in 1952 U.S.C.C.A.N. 2394, 2399). 
 6. Id. at 185. 
 7. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
 8. O’Reilly v. Morse, 56 U.S. 62 (1853) (holding Morse’s claim eight 
invalid as too broad because it attempted to claim any machinery that used 
electromagnetism for making or printing intelligible characters, signs, or 
letters, at any distance. The claim was too broad because it precluded others 
from using any process or machine, including ones that Morse had not 
invented or described, to accomplish the result. Further, the claim was too 
broad because Morse had not discovered that the form of machinery did not 
matter because electric current would always print at a distance). C.f. Dolbear 
v. Am. Bell Tel. Co., 126 U.S. 1 (1887) (finding claim five valid and 
distinguishing it from claim eight in Morse because Bell only claimed the 
transmission of vocal sounds by means of undulations in continuous current. 
Further, the Court noted that at the time, for all anyone knew, that change in 
current was required for the current to serve as a medium for speech 
transmission. Because Bell was the first to discover how to change the current, 
and he claimed changing the current in the way described in the claim to 
transmit sound, he was entitled to the patent.). Gottschalk v. Benson, 409 U.S. 
63 (1972) (holding a method for converting binary coded decimal numerals into 
pure binary numerals unpatentable subject matter because it was merely a 
mathematical formula without practical application except in connection with 
a digital computer.). Parker v. Flook, 437 U.S. 584 (1978) (holding the claim at 
issue, which recited a new method for calculating alarm limit values, invalid 
because the only novel thing in the method was the mathematical formula or 
algorithm, and was therefore not patentable subject matter).  Diehr, 450 U.S. 
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the Court has had in determining when to apply the judicial 
exceptions to § 101, the standard for meeting the requirement 
of § 101 is quite low, and the issue is rarely litigated.9 
THE CASE 
Researchers at University Patents Inc. (UPI) discovered a 
relationship between an elevated level of total homocysteine 
and a deficiency in B vitamins, specifically B12 (cobalamin) and 
folic acid (folate).10  Serious health risks, including vascular 
disease, cognitive dysfunction, birth defects and cancer, can 
result from a deficiency in these vitamins.11  If, however, the 
deficiency is caught early enough, vitamin supplements can 
easily treat the deficiency.12  UPI inventors developed a method 
of assaying for total homocysteine along with other metabolites 
that could indicate which vitamin may be deficient.13  In 
general, the ‘658 patent was directed to the developed 
diagnostic method for determining whether deficiencies in B12 
and folic acid existed.14  Independent claim thirteen, the sole 
claim at issue in the case, recited: 
“A method for detecting a deficiency of cobalamin or folate 
in warm-blooded animals comprising the steps of: assaying a 
body fluid for an elevated level of total homocysteine; and 
correlating an elevated level of total homocysteine in said body 
fluid with a deficiency of cobalamin or folate.”15 
CTI, UPI’s successor, acquired the rights to the patent 
before it issued.16  CTI granted a non-exclusive license to the 
patent to Metabolite Laboratories, Inc. (Metabolite).17  Under 
at 175-76 (holding that while a mathematical formula by itself is not 
patentable subject matter, if a claim containing a mathematical formula 
implements it in a process that when considered as a whole performs a useful 
function, the claim is then patentable.  Further the Court found that it was 
irrelevant if each step in a process was itself unpatentable, if the process 
taken as a whole constituted patentable subject matter). 
 9. PRATISING LAW INSTITUTE, Overview of Patent Litigation, 798 PLI/PAT 
281, 325 (2004). 
 10. Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 
1358 (Fed. Cir. 2004). 
 11. Id. 
 12. Id. 
 13. Id. 
 14. U.S. Patent No. 4,940,658 (filed Nov. 20, 1986). 
 15. Metabolite, 370 F.3d at 1358–59. 
 16. Brief for Petitioner at 6, Lab. Corp. of Am. Holdings v. Metabolite 
Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2005 WL 3543099. 
 17. Id. 
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the licensing agreement Metabolite was permitted to sub-
license the patent to other parties, which Metabolite did.18  
Metabolite sublicensed the patent to Laboratory Corporation of 
America Holdings (LabCorp, formerly Roche Biomedical 
Laboratories).19  In 1992, LabCorp began using the assaying 
method covered by the ‘658 patent and paying the required 
royalties to Metabolite.20  In 1998, however, LabCorp also 
began using a method developed by Abbott Laboratories 
(Abbott) for testing for homocysteine alone (without the other 
metabolites), which was useful in diagnosing heart disease.21  
LabCorp continued to pay royalties to Metabolite whenever it 
used the assaying method claimed in the ‘658 patent, but 
LabCorp did not pay royalties when it used the Abbott test.22 
In May 1999, CTI, the patent holder, sued LabCorp for 
infringement, inducing infringement and contributory 
infringement of claim thirteen.23  Metabolite sued LabCorp for 
breach of the licensing agreement,24 arguing that the 
agreement only permitted LabCorp to use other methods for 
assaying for homocysteine levels if the other tests did not 
infringe any valid claim of the ‘658 patent.25  The district court 
granted LabCorp’s summary judgment motion on direct 
infringement because LabCorp itself did not perform the 
correlating step required by claim thirteen.26  The contributory 
infringement charge remained, however, because LabCorp 
allegedly induced physicians to infringe claim thirteen 
whenever physicians viewed total homocysteine test results 
and concluded the patient either did or did not have a vitamin 
deficiency.27  The jury found claim thirteen valid and also 
 18. Id. 
 19. Id. at 7.  LabCorp is a large clinical reference laboratory that conducts 
tests ordered by health care professionals used in diagnosing and treating 
patients.  Id. at 6. 
 20. Id. at 7. 
 21. Metabolite, 370 F.3d at 1359; see also Brief for Petitioner, supra note 
16, at 8. The correlation between elevated levels of homocysteine and an 
elevated risk of heart disease had been known since 1969 or earlier.  Id. 
 22. Brief for Petitioner, supra note 16, at 9. 
 23. Brief for Respondents at 8, Lab. Corp. of Am. Holdings v. Metabolite 
Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2006 WL 303905. 
 24. Id. at 8. 
 25. Brief for Petitioner, supra note 16, at 7. 
 26. Id. 
 27. See Metabolite, 370 F.3d at 1364. 
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found that LabCorp willfully induced infringement of the 
claim.28  LabCorp was ordered to pay nearly $5.7 million in 
damages.29  LabCorp’s motion for judgment as a matter of law 
was denied and the district court enjoined LabCorp from using 
the Abbott test.30 LabCorp appealed.31  On appeal, the Federal 
Circuit affirmed the district court’s ru
LabCorp petitioned the Supreme Court of the United 
States for writ of certiorari.33 The Court granted cert only as to 
question three of Petitioner’s Petition for Writ of Certiorari:34  
Whether a method patent setting forth an indefinite, undescribed, 
and non-enabling step directing a party simply to ‘correlate’ test 
results can validly claim a monopoly over a basic scientific 
relationship used in medical treatment such that any doctor 
necessarily infringes the patent merely by thinking about the 
relationship after looking at a test result.35   
After the parties filed their briefs, the Court invited the 
Solicitor General, on behalf of the government, to express its 
views on whether the patent was invalid because one cannot 
patent laws of nature, natural phenomena, and abstract 
ideas.36  
After hearing oral arguments on the case from the parties, 
as well as the Solicitor General, the Court dismissed the writ as 
improvidently granted on June 22, 2006.37  Justice Breyer, 
joined by Justices Stevens and Souter, wrote a vehement 
dissent.38 
THE DISMISSAL 
While the Court did not provide a reason for dismissing the 
writ as improvidently granted, it is likely that the Court was 
 28. Id. at 1359. 
 29. Id. 
 30. Id. 
 31. Id. 
 32. Id. at 1372. 
 33. Petition for Writ of Certiorari at *i, Lab. Corp. of Am. Holdings v. 
Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2004 WL 2505526. 
 34. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. at 543. 
 35. Petition for a Writ of Certiorari, supra note 33, at *i. 
 36. Brief for United States as Amicus Curiae, Lab. Corp. of Am. Holdings 
v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2005 WL 
3533248. 
 37. Lab. Corp of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. at 
2921. 
 38. Id. 
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heavily influenced by the arguments made in the briefs of the 
Respondent (collectively Metabolite), and the Solicitor General, 
which strenuously requested that the Court dismiss the writ on 
procedural grounds.39  They argued that the writ was granted 
to decide a question which was never addressed in either of the 
lower courts, namely § 101 subject matter patentability.40  
LabCorp never specifically cited § 101 in its briefs or oral 
arguments in the lower courts, nor did it ever state that claim 
thirteen covered unpatentable subject matter.41  The jury was 
not instructed to reach a verdict on whether claim thirteen 
recited patentable subject matter.42  The Federal Circuit did 
not consider whether claim thirteen recited patentable subject 
matter.43  In Metabolite’s Supreme Court brief it recited a 
panoply of authority from the Federal Rules of Civil Procedure, 
to the Patent Act, to the Supreme Court’s own precedent in 
order to demonstrate the inappropriateness of reviewing an 
issue which was not pleaded, argued, or considered in the lower 
courts.44 
The Solicitor General, in its requested brief, also vigorously 
argued that the validity of claim thirteen under § 101 should 
not be considered by the Court because the issue was “neither 
pressed nor passed upon below.”45  Specifically, the Solicitor 
General argued that failure to bring up a § 101 defense 
potentially limited the district court’s claim construction of 
claim thirteen so as to make the record incomplete for purposes 
of assessing whether claim thirteen recited patentable subject 
 39. Transcript of Oral Argument, Lab. Corp. of Am. Holdings v. 
Metabolite Labs., 126 S. Ct. 2921 (2006) (No. 04-607), available at  
http://www.supremecourtus.gov/oral_arguments/argument_transcripts/04-
607.pdf. The Supreme Court spent a significant amount of time at oral 
arguments trying to determine whether Petitioner’s § 112 arguments, which 
were pled and argued in the lower courts, legitimately incorporated the issue 
before the Court, namely whether claim thirteen recited patentable subject 
matter.  Id. 
 40. Brief for the United States as Amicus Curiae, supra note 36; Brief for 
the Respondents, supra note 23, at 19.  LabCorp argued, as affirmative 
defenses, that claim thirteen was invalid, unenforceable and/or void for 
lacking novelty, nonobviousness, definiteness, lacking an adequate written 
description and being insufficiently enabling.  Id. at 8. 
 41. Id. 
 42. Id. at 8–9. 
 43. Id. at 10. 
 44. Brief for Respondents, supra note 23, at 20–26. 
 45. Brief for the United States as Amicus Curiae, supra note 40, at 5. 
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matter.46 
Further, the Solicitor General noted that the Federal 
Circuit has interpreted the Court’s holding in Diehr to 
substantially limit its holding in Flook, so that what would 
have been unpatentable subject matter under Flook because all 
that was recited was a mathematical formula, is now 
patentable under Diehr as long as the claim containing the 
formula implements a process that taken as a whole performs a 
useful function.  The Solicitor General stated that the PTO had 
issued “numerous” patents based on the Federal Circuit’s 
interpretation of those cases.47  The Solicitor General cautioned 
that overturning the PTO’s approach to patentable subject 
matter could “call into question a substantial number of patent 
claims and undermine the settled expectations of numerous 
participants in technology-based industries.”48  The Solicitor 
General argued that this was an inappropriate case for 
“examining such a fundamentally important issue,” because the 
issue was not litigated below, and consequently the record was 
incomplete on the issue.49 
THE DISSENT 
Justice Breyer, joined by Justices Stevens and Souter, 
dissented from the Court’s dismissal of the writ.50  Justice 
Breyer would have found claim thirteen invalid because it does 
not claim patentable subject matter, but rather attempts to 
claim a natural phenomenon, which is impermissible.51  He 
argued that the Court should have decided the case because the 
Court had the authority to decide the issue, which was not 
“unusually difficult”, and that “those who engage in medical 
research, who practice medicine, and who as patients depend 
upon proper health care, might well benefit from this Court’s 
 46. Id. at 9–16. The district court, had it known § 101 was at issue, may 
have required that the parties provide more information so it could determine 
whether or not the claim term “assay” could mean that assaying bodily fluid 
necessarily involves the transformation of matter from one state to a different 
state, and if “assay” could be so construed, that would weigh heavily in favor of 
claim thirteen reciting patentable subject matter under the Federal Circuit’s 
interpretation of Benson, 409 U.S. 63, and Diehr, 450 U.S. 175. 
 47. Id. at 13–14. 
 48. Id. at 14. 
 49. Id. at 14–15. 
 50. Lab. Corp. of Am. Holdings v. Metabolite Labs.,126 S. Ct. at  2921. 
 51. Id. at 2927. 
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ssue and not dismiss the 
writ
ave claim thirteen from 
                  
 
authoritative answer.”52 
The dissent agreed with LabCorp’s argument that LabCorp 
did present the issue of subject matter to the Federal Circuit, 
because subject matter was necessarily incorporated in its § 
112 invalidity arguments.53  Because the heart of the argument 
was presented below he found the procedural reason for 
dismissing the result “tenuous.”54  Justice Breyer 
acknowledged that the Federal Circuit’s specific review of the 
issue would have been helpful but that the case should have 
been decided anyway because it was fully briefed by the parties 
and many amici, and the record was thorough and complete.55  
Finally, he argued that he believed the “important 
considerations of the public interest – including that of 
clarifying the law in this area sooner rather than later” was a 
significant reason to decide the i
.56 
While admitting that the law surrounding the exceptions 
to patentable subject matter “is not easy to define,” he 
concluded that the process described in claim thirteen was an 
easy case, and did not require a complex interpretation of the 
natural phenomenon line of cases.57  Clearly, he argued, the 
correlation between elevated homocysteine levels and a 
deficiency in one or both of the B vitamins (folic acid and B12) 
was a natural phenomenon.58  He rejected Metabolite’s 
argument that it patented a process that included transforming 
matter from one state to another, because claim thirteen did 
not claim the assaying step.59  In fact, claim thirteen claimed 
any method of assaying for total homocysteine levels, whether 
that method was patented, unpatented, or not yet invented.60  
Claim thirteen did not cover the method for testing itself, thus, 
the fact that the method for testing might transform bodily 
fluid from one state to another cannot s
                                        
. 
. Holdings v. Metabolite Labs., 126 S. Ct. at 2926. 
7. 
t 2927. 
 52. Id. at 2922. 
 53. Id. at 2925–6
 54. Id. at 2925. 
 55. Id. at 2926. 
 56. Lab. Corp. of Am
 57. Id. at 2926–2
 58. Id. a
 59. Id. 
 60. Id. 
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ing unpatentable subject matter.61 
Justice Breyer also rejected Metabolite’s argument that 
claim thirteen recited a useful, concrete and tangible result, 
which the Federal Circuit held adequate to save a claim from 
subject matter invalidity in State Street Bank & Trust v. 
Signature Financial Group, Inc..62  Significantly, Justice 
Breyer acknowledged that the case stood for that proposition, 
but that “this Court has never made such a statement and, if 
taken literally, the statement w
rt has held the contrary.”63 
Even so, assuming arguendo that claim thirteen met 
general requirements for process patentability, Justice Breyer 
stated that the claim would still be invalid because it is simply 
nothing more than “the natural law at issue in the abstract 
patent language of a ‘process.’”64  Justice Breyer concluded the 
dissent by stating that if he was correct in finding claim 
thirteen unpatentable, then the medical community and 
patients are threatened by permitting the claim to stand.65  He 
continued to state that if he was not correct that claim thirteen 
is unpatentable, then the medical community would still be 
aided by clarifying confusion in this area of law, “diminish[ing] 
legal uncertainty in the area” that could potentially affect a 
significant number of existing patents, and providing Congress 
with the knowledge needed t
SOME OF THE CONCERNS 
The Supreme Court’s grant of certiorari to consider subject 
matter patentability in this case had some anxious and others 
optimistic.  For instance in the amicus brief filed by the Federal 
Circuit Bar Association (FCBA) in support of respondents, 
FCBA argued that according to the Federal Circuit few cases 
fall into the judicially created exceptions to § 101 (laws of 
nature, natural phenomena, and abstract ideas) largely 
because those exceptions have been difficult to apply to specific 
 & Trust v. Signature Fin. Group, Inc., 149 F.3d 1368, 
ir. 1998)). 
. 
 61. Lab. Corp. of Am. Holdings v. Metabolite Labs, 126 S. Ct. at 2927–8. 
 62. Lab. Corp. of Am. Holdings v. Metabolite Labs., 126 S. Ct. at 2928 
(citing to State St. Bank
1373 (Fed. C
 63. Id. 
 64. Id. 
 65. Id. at 2928–9
 66. Id. at 2929. 
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n this case could have “significant economic 
repe
                                                          
 
cases.67  The FCBA argued that “history shows that judicial 
exceptions to § 101 tend to create more problems than they 
solve.68  If “Congress deemed it necessary, it could amend § 
101, but it has left the scope of § 101 unaltered 
notwithstanding a debate that is far older than the statute 
itself.”69  The FCBA believes the Federal Circuit’s holding in 
this case should stand, an
edent in this area should not be disturbed.70 
Conversely, in an amicus brief filed by Financial Services 
Industry (FSI) in support of reversal, FSI argued that the 
Federal Circuit had “effectively nullified” the Supreme Court’s 
“reservation of abstract ideas to the public domain – and 
attracted significant academic criticism in the process.”71  FSI 
argued that clearly unpatentable claims under a “common-
sense” reading of the Court’s holding in Diehr could now be 
easily patented under the Federal Circuit’s current 
interpretation of § 101.72  FSI argued that allowing claim 
thirteen to stand would mean “the free-for-all in the patenting 
of abstract business methods would continue and undoubtedly 
hinder innovation and efficiency in the financial services 
industry for decades.”73  More generally, it warned that the 
Court’s decision i
rcussions.”74 
American Clinical Laboratory Association (ACLA) argued 
in its amicus brief in support of petitioner that if the Court 
found claim thirteen valid it would mean “any researcher who 
discovers a chemical association in the human body will be able 
to claim a monopoly over any future diagnostic test based on 
that association.”75  ACLA stated that this prohibition would 
. Metabolite Labs., Inc., 126 
. 2006) (No. 04-607), 2006 WL 303906. 
Metabolite Labs., Inc., 126 S. Ct. 
9 (No. 04-607), 2005 WL 3543097. 
t 1. 
 
 67. Amicus Curiae Brief of the Federal Circuit Bar Association in Support 
of Respondents at 15, Lab. Corp. of Am. Holdings v
S Ct. 2921 (
 68. Id. 
 69. Id. 
 70. Id. 
 71. Brief of Financial Services Industry Amici Curiae in Support of 
Reversal at 9, Lab. Corp. of Am. Holdings v. 
2 21 (2006) 
 72. Id. 
 73. Id. a
 74. Id. 
 75. Brief of the American Clinical Laboratory Association as Amicus 
Curiae in Support of Petitioner at 1-2, Lab. Corp. of Am. Holdings v.
DAWSON M. Metabolite Labs and Patentable Subject Matter: A Review of Federal Circuit and 
PTO Precedent was Narrowly Averted, but for How Long? MINN. J.L. SCI. & TECH. 
2006;8(1):345-356.  
2007]  METABOLITE & PATENTABLE SUBJECT MATTER 355 
 tests and patients’ access to those tests would 
suff
 and development in personalized medicine 
                                                          
either entirely preclude further innovation and improvements 
in diagnostic tests that are based upon a patented correlation, 
or that further innovation and improvement, if they do occur at 
all, will only occur at a “higher price and on a limited basis.”  It 
continued that “either way, laboratories’ ability to provide new 
lifesaving
er.”76 
On the other hand, Perlegen Sciences, Inc.77 (Perlegen) and 
Mohr, Davidow Ventures78 (MDV) argued in their amicus brief 
in support of respondents that economic and scientific 
considerations argue in favor of upholding the Federal Circuit 
and PTO’s current subject matter interpretation, and that 
claim thirteen should be held to recite patentable subject 
matter.79  It argued that a holding that claim thirteen did not 
recite patentable subject matter “could significantly diminish 
Perlegen’s incentive to engage in research and to develop 
diagnostic methods for determining the patient population for 
which particular drugs are safe and effective.”80  MDV argued 
that it provided funding to diagnostic start-ups knowing that 
processes such as those recited in claim thirteen “have been 
consistently granted patent protection over an extended period 
of time.”81  MDV stated that if claim thirteen, and those like it, 
is found invalid it “could limit the economic viability of 
companies seeking to research and develop diagnostic methods 
like that identified in Claim 13 . . . .”82  MDV concluded that 
venture capitalists “would have significantly diminished 
incentives to invest in the very companies that are on the 
forefront of research
 Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2005 WL 3543098. 
. Metabolite Labs., Inc., 126 S. 
rcialize novel 
and Mohr, Davidow 
 Respondents, supra note 77, at 1. 
t 1–2. 
and Mohr, Davidow 
ort of Respondents, supra note 77, at 2. 
Metabolite Labs.,
 76. Id. at 2. 
 77. Perlegen is “a leader in personalized medicine, working to provide safe 
and effective medications to patients worldwide.”  Brief for Amici Curiae 
Perlegen Sciences, Inc., and Mohr Davidow Ventures in Support of 
Respondents at 1, Lab. Corp. of Am. Holdings v
Ct. 2921 (2006) (No. 04-607), 2006 WL 303908. 
 78. MVD is a “leading Silicon Valley-based venture capital firm 
specializing in predictive diagnostics and personalized medicine.”  Id. at 2.  
MDV works with academic institutions that invent and comme
technologies and business models helping to build start-ups.  Id. 
 79. Brief for Amici Curiae Perlegen Sciences, Inc., 
Ventures in Support of
 80. Id. a
 81. Id. 
 82. Brief for Amici Curiae Perlegen Sciences, Inc., 
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and diagnostics.”83 
issent of three Justices, the only ones to 
disc
 the matter up again, all will benefit from more 
certainty in the area of what constitutes patentable subject 
matter. 
                                                          
CONCLUSION 
There are many concerns about the doctrine of patentable 
subject matter, with the above concerns only presenting a 
sample of the potential issues that will face the Court should it 
decide to take up this issue in the near future.  The mere fact 
that the Court granted cert on this issue after a quarter 
century of silence on the matter would seem to indicate the 
Court believes the issue needs to be altered, or at lease 
clarified.  The fervent d
uss the issue on its merits, is also telling of where the Court 
may go with the issue. 
The evolution of science and technology has forced the 
Court to look at subject matter anew in the past.  More than 
twenty-five years have passed since the doctrine has been 
revisited by the Court, and we find ourselves facing 
dramatically different scientific and technological 
advancements, which could not have been appreciated when 
Diehr was decided.  Regardless of what the Court decides when 
it takes
 83. Id. at 3. 
